M. Wilschanski - Concepedia

Author

M. Wilschanski

Also Known As

M WILSCHANSKI, M Wilschanski, M. Wilschanski, Micheal Wilschanski

Publications

914

Citations

H-Index

Concepts

All Affiliations

M. Wilschanski is an author at Hôpital Necker-Enfants Malades specializing in medicine, pulmonary disease, and clinical trials.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	76
2	Immunology	1	1	11
3	Pathology	1	1	11
4	Pharmacology	1	1	11
5	Pulmonary Disease	1	1	65

M. Wilschanski

Publications

498

Citations

H-Index

Page 1

	Year	Citations
Management Guidelines of Eosinophilic Esophagitis in Childhood Anna Papadopoulou, Sibylle Koletzko, Robert Heuschkel, Journal of Pediatric Gastroenterology and Nutrition	2013	334
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF) Michael W. Konstan, Donald R. VanDevanter, Steven M. Rowe, Journal of Cystic Fibrosis Pulmonary CareAct CfClinical TrialsNonsense-mutation Cystic FibrosisMedicine	2020	65
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction Isabelle Sermet‐Gaudelus, E. Girodon, F. Vermeulen, Journal of Cystic Fibrosis Ecfs StandardsCftr DysfunctionDiagnostic Criteria	2022	46
Primary sclerosing cholangitis in 32 children: Clinical, laboratory, and radiographic features, with survival analysis*1 M. Wilschanski Hepatology	1995	30
Reaching the diagnosis of cystic fibrosis--the limits of the spectrum. Yitzchak Lotem, A. Barak, Huda Mussaffi, PubMed	2000	12
PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF M. Wilschanski, S. Armoni, Yasmin Yaakov, Journal of Cystic Fibrosis Gene TherapiesPtc124 TreatmentNonsense-mutation-mediated CfClinical TranslationGenetic Disorder	2008	11

Page 1